French beauty group Clarins has established a dedicated investment fund targeting India's prestige skincare and makeup market — a strategic move backed by 35% growth last year and a three-year CAGR of 42%, and modelled on the same long-cycle approach the company used to build its China business.
# Clarins Launches India Fund as Prestige Beauty Bets Shift
Clarins, the French family-owned beauty group and one of the world's leading independent prestige skincare companies, has established a dedicated investment fund for India — a structural commitment to what its CEO, Jonathan Zrihen, has described as the brand's next major growth market. The fund, reported in July 2026, is designed to support Clarins' India operations over a five-to-ten-year horizon, following what has been one of the brand's strongest recent performance records: 35% revenue growth in India last year and a compound annual growth rate of approximately 42% over the last three years.
The establishment of the fund is not an isolated tactical move. It is a strategic rebalancing — away from a China-centric Asia model toward a more diversified growth architecture in which India assumes a central role.
Clarins currently generates approximately one third of its €2 billion global revenue from Asia, with China historically the dominant contributor. But China's beauty market has entered a period of plateauing growth, intensified domestic competition from local brands, and shifting consumer sentiment toward Chinese-origin products. The structural headwinds affecting multinationals in China are well documented and, in Clarins' case, make India's trajectory more commercially significant by contrast.
The decision to model India's fund structure on the approach Clarins used to build its China business two decades ago is significant. It signals that Clarins views India not as an opportunistic near-term revenue play, but as a market requiring the same patient, relationship-driven market-building that it committed to in China in the early 2000s — and which eventually produced a substantial share of its global revenue.
For India-based B2B players, this framing matters. A global house committing to a decade-long fund cycle in India is not looking for transactional supplier relationships. It is looking for manufacturing partners, distributor relationships, and formulation co-development capacities that can scale alongside its India ambitions over an extended period.
Clarins is primarily known in India — and globally — as a prestige skincare brand. Its positioning in plant-based, high-performance formulations has resonated with the Indian premium consumer's increasing preference for ingredient-driven, nature-aligned skincare. But the fund's stated priority is to accelerate growth in the makeup segment, which Clarins' management expects to outpace its traditional skincare business in India.
The brand is targeting a 10% market share in the prestige skincare category and a 6% to 7% share in the prestige makeup segment over the next decade. These are not modest ambitions in a market where prestige colour cosmetics is a relatively underpenetrated category, but one that is rapidly expanding as Indian consumers — particularly urban millennials and Gen Z — build multi-step routines that include high-performance colour products alongside their skincare.
The makeup expansion is strategically coherent with India's consumer trajectory. Premium skincare in India at the ₹1,500–₹3,000 price point is already growing at approximately 22% CAGR — demonstrating that the willingness to spend on prestige formulations exists and is deepening. Makeup at equivalent price points is following a similar curve, and a brand with Clarins' skincare equity is well positioned to cross-sell into colour for an existing, loyal skincare consumer base.
India's luxury and prestige beauty market is valued at approximately USD 5.1 billion in 2025–2026, within a broader beauty and personal care market estimated at USD 21.5–23.7 billion. The prestige segment is growing faster than the overall market, driven by four structural factors: rising household incomes, expanding retail infrastructure in Tier-1 and Tier-2 cities, a digitally sophisticated consumer base that discovers global brands through social media before they are available domestically, and a post-pandemic shift in spending preference toward quality over quantity.
Clarins is not alone in making India a priority. L'Oréal, Estée Lauder, and Shiseido have all significantly increased their India resource allocation. Fenty Beauty, Rare Beauty, Huda Beauty, and Lush have either entered or materially expanded their India presence in the last two years. The pattern is consistent: global houses that built their international growth models in the 2000s around China are now rebalancing toward India with structural, multi-year commitments rather than exploratory market entries.
What differentiates Clarins' India positioning from some of its multinational peers is the philosophical alignment between its brand identity and Indian consumer values. Clarins' founding identity — centred on plant-based formulation science, botanical sourcing, and a nature-sensitive approach to skin health — resonates authentically with the holistic wellness orientation of a significant proportion of India's premium skincare consumer base.
Zrihen has explicitly cited this alignment as a strategic advantage for India, noting that Indian consumers' view of beauty as integrated with nature and wellness creates a natural audience for Clarins' plant-heritage positioning. This is not a superficial marketing claim; Clarins' formulation philosophy — which draws on over 230 plant ingredients and has maintained botanical science as the core of its R&D approach since 1954 — is a genuine structural differentiator in a prestige market where consumers are increasingly literate about ingredient provenance.
Clarins' decade-long fund commitment to India creates concrete downstream demand across the supply chain that B2B players should map against their current capabilities.
India's prestige beauty market is entering a phase of competitive intensity driven by global capital. Clarins' fund is one of several signals that this is not a market multinationals are testing — it is a market they are building for.
Wipro Consumer Care International's acquisition of S Brands Consumer Care in the Philippines — its 16th global deal and second in the market — pushes its Philippines revenue past the ₹1,000-crore mark, and adds six category-leading local brands to a Southeast Asia portfolio being built with patient, acquisition-led precision.
Asaya’s fivefold annual growth highlights a crucial structural pivot in India's BPC segment away from outsourced third-party formulation toward proprietary in-house chemical architecture and clinical validation.
